Via a collaboration with Nasa, Auxilium has installed a 3D printer on the ISS to test the promise of manufacturing in ...

“We are pleased to welcome Jesse to the Axogen team," said Michael Dale, Chief Executive Officer, and Director, Axogen. "His extensive experience in regulatory strategy and deep understanding of the ...

The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

The injuries started early for the Green Bay Packers in their 22-10 playoff loss to the Philadelphia Eagles on Sunday and they never stopped all the way to the final moments. One by one ...

SPR announces four featured abstracts that will be presented at the upcoming North American Neuromodulation Society (NANS) Annual Meeting in Orlando, January 29 – February 1. All the abstracts contain ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Four in every 10 cancer patients treated with chemotherapy develop severe peripheral nerve pain, a new review suggests.